MA32480B1 - Compositions pédiatriques pour le traitement de la sclérose en plaques - Google Patents

Compositions pédiatriques pour le traitement de la sclérose en plaques

Info

Publication number
MA32480B1
MA32480B1 MA33524A MA33524A MA32480B1 MA 32480 B1 MA32480 B1 MA 32480B1 MA 33524 A MA33524 A MA 33524A MA 33524 A MA33524 A MA 33524A MA 32480 B1 MA32480 B1 MA 32480B1
Authority
MA
Morocco
Prior art keywords
treatment
children
compositions
multiple sclerosis
sclerosis
Prior art date
Application number
MA33524A
Other languages
Arabic (ar)
English (en)
Inventor
Marie-Claude Bastien
John Kovarik
Robert Schmouder
Olivier David
Goeril Karlsson
Thomas Bouillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32480(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32480B1 publication Critical patent/MA32480B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comportent un composé de 2-amino-2-[2-(4-c2-20-alkyl-phényl)éthyl]propane-1,3-diol ou un sel de qualité pharmaceutique de celui-ci, et l'utilisation de celui-ci pour traiter, prévenir ou retarder la progression d'une sclérose en plaques chez un patient pédiatrique ou un patient souffrant d'un état précis.
MA33524A 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques MA32480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20
PCT/US2009/047885 WO2009155475A1 (fr) 2008-06-20 2009-06-19 Compositions pédiatriques pour le traitement de la sclérose en plaques

Publications (1)

Publication Number Publication Date
MA32480B1 true MA32480B1 (fr) 2011-07-03

Family

ID=40974366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33524A MA32480B1 (fr) 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques

Country Status (16)

Country Link
US (11) US20110152380A1 (fr)
EP (3) EP3011958A1 (fr)
JP (7) JP2011525189A (fr)
KR (4) KR20170081755A (fr)
CN (2) CN104800196A (fr)
BR (1) BRPI0914139A2 (fr)
CA (1) CA2728514C (fr)
CL (1) CL2010001463A1 (fr)
IL (2) IL209725A (fr)
MA (1) MA32480B1 (fr)
MX (1) MX2010014223A (fr)
NZ (1) NZ589618A (fr)
RU (1) RU2562571C2 (fr)
SG (1) SG10201406263SA (fr)
WO (1) WO2009155475A1 (fr)
ZA (1) ZA201008478B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
BRPI0921826A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag compostos orgânicos
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
AU2010300919A1 (en) 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
PH12013501442B1 (en) 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994008943A1 (fr) * 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. Compose 2-amino-1,3-propanediol et immunosuppresseur
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
WO2000049008A1 (fr) 1999-02-20 2000-08-24 Astrazeneca Ab Derives nitriles di- et tripeptidiques, utiles en tant qu'inhibiteurs des cathepsines l et s
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
WO2000049007A1 (fr) 1999-02-20 2000-08-24 Astrazeneca Ab Derives acetamido acetonitriles en tant qu'inhibiteurs de la cathepsine l et/ou s
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (fr) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Traitement combiné de l'esclerose multiple avec l'interferon et l'hormone de croissance
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
ES2219388T3 (es) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-epi-rapalogos.
WO2001019796A1 (fr) 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Composes et compositions pharmaceutiques utilises comme inhibiteurs de la cathepsine s
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
EP1309591B1 (fr) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Pyrazoles substitues
NZ524192A (en) 2000-08-14 2005-02-25 Ortho Mcneil Pharm Inc Substituted pyrazoles
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
EP1326848A1 (fr) 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Derives de dihydropyrimidine utilises comme inhibiteurs de cysteine protease
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
WO2003024924A1 (fr) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Nouveaux composes et nouvelles compositions utiles comme inhibiteurs de la cathepsine
WO2003024923A1 (fr) 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Composes sulfonamide en tant qu'inhibiteurs de protease
EP1434769A2 (fr) 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
JP2005508979A (ja) 2001-10-29 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
US7371747B2 (en) 2001-11-13 2008-05-13 Merck Frosst Canada & Co. Cyanoalkylamino derivatives as protease inhibitors
RU2004117877A (ru) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) Олигопептиды и композиции, содержащие их, в качестве ингибиторов катепсина s
EP1389480A1 (fr) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
BR0314760A (pt) * 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
BRPI0409250B8 (pt) 2003-04-08 2022-01-18 Mitsubishi Pharma Corp Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
US20050009052A1 (en) * 2003-04-22 2005-01-13 Irm Llc, A Delaware Limited Liability Company Differential tag length analysis of cell proliferation
WO2005025553A2 (fr) * 2003-09-12 2005-03-24 Neuronova Ab Traitement de maladies ou de lesions du systeme nerveux avec le fty720
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PT3103448T (pt) 2006-09-26 2019-07-12 Novartis Ag Composições farmacêuticas que compreendem um modulador de s1p
CN104800196A (zh) 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物

Also Published As

Publication number Publication date
IL209725A (en) 2016-11-30
SG10201406263SA (en) 2015-02-27
KR20180017232A (ko) 2018-02-20
IL209725A0 (en) 2011-02-28
US20180177747A1 (en) 2018-06-28
US20200197334A1 (en) 2020-06-25
CA2728514A1 (fr) 2009-12-23
CN102076335A (zh) 2011-05-25
ZA201008478B (en) 2012-01-25
EP3545953A1 (fr) 2019-10-02
US20170333368A1 (en) 2017-11-23
EP3011958A1 (fr) 2016-04-27
MX2010014223A (es) 2011-01-21
CA2728514C (fr) 2020-08-11
EP2303250A1 (fr) 2011-04-06
JP2011525189A (ja) 2011-09-15
AU2009259950A1 (en) 2009-12-23
KR20110020928A (ko) 2011-03-03
IL248919B (en) 2018-12-31
JP2020063269A (ja) 2020-04-23
JP2017122106A (ja) 2017-07-13
BRPI0914139A2 (pt) 2015-10-20
RU2011101771A (ru) 2012-07-27
US20190117593A1 (en) 2019-04-25
RU2562571C2 (ru) 2015-09-10
US20160022611A1 (en) 2016-01-28
US20190358178A1 (en) 2019-11-28
CL2010001463A1 (es) 2011-05-06
IL248919A0 (en) 2017-01-31
US20130230489A1 (en) 2013-09-05
US20160206574A1 (en) 2016-07-21
JP2023153786A (ja) 2023-10-18
JP2018184424A (ja) 2018-11-22
KR20170081755A (ko) 2017-07-12
KR20160131126A (ko) 2016-11-15
WO2009155475A1 (fr) 2009-12-23
US20210023027A1 (en) 2021-01-28
CN104800196A (zh) 2015-07-29
JP2015107984A (ja) 2015-06-11
US20110152380A1 (en) 2011-06-23
JP2021152016A (ja) 2021-09-30
NZ589618A (en) 2012-09-28
US20170128389A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
MA32480B1 (fr) Compositions pédiatriques pour le traitement de la sclérose en plaques
WO2010055028A3 (fr) Composés organiques
EP2249861A4 (fr) Traitement de maladies neurodégénératives avec de la progranuline (pgrn)
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2010115041A3 (fr) Compositions orales utilisables dans le cadre du traitement de la sensibilité dentaire et leurs procédés d'utilisation et de fabrication
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
SI1824563T1 (sl) Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatične encefalopatije
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
WO2010036395A3 (fr) Traitement de l’exposition aux organophosphates au moyen de composés de tétrahydroindolone arylpipérazine
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
WO2013098416A3 (fr) Composes anti-douleur
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
EP2667885A4 (fr) Compositions et procédés pour apporter ou moduler le goût sucré, et procédés de recherche systématique s'y rapportant
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
WO2012100043A3 (fr) Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
EA201170267A1 (ru) Способ лечения гиперчувствительности зубов
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound